190 related articles for article (PubMed ID: 33326835)
21. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.
Wang Y; Wang W; Xu L; Zhou X; Shokrollahi E; Felczak K; van der Laan LJ; Pankiewicz KW; Sprengers D; Raat NJ; Metselaar HJ; Peppelenbosch MP; Pan Q
Antimicrob Agents Chemother; 2016 May; 60(5):2834-48. PubMed ID: 26926637
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific.
Xu L; Zhou X; Peppelenbosch MP; Pan Q
Arch Virol; 2015 Feb; 160(2):435-9. PubMed ID: 25476751
[TBL] [Abstract][Full Text] [Related]
23. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV.
Jagst M; Gömer A; Todt D; Steinmann E
Antiviral Res; 2024 Jul; 227():105922. PubMed ID: 38825018
[TBL] [Abstract][Full Text] [Related]
24. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol.
Glitscher M; Himmelsbach K; Woytinek K; Johne R; Reuter A; Spiric J; Schwaben L; Grünweller A; Hildt E
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865243
[TBL] [Abstract][Full Text] [Related]
26. Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.
Allweiss L; Gass S; Giersch K; Groth A; Kah J; Volz T; Rapp G; Schöbel A; Lohse AW; Polywka S; Pischke S; Herker E; Dandri M; Lütgehetmann M
J Hepatol; 2016 May; 64(5):1033-1040. PubMed ID: 26805671
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis E Virus Mutations: Functional and Clinical Relevance.
van Tong H; Hoan NX; Wang B; Wedemeyer H; Bock CT; Velavan TP
EBioMedicine; 2016 Sep; 11():31-42. PubMed ID: 27528267
[TBL] [Abstract][Full Text] [Related]
28. Effective inhibition of hepatitis E virus replication in A549 cells and piglets by RNA interference (RNAi) targeting RNA-dependent RNA polymerase.
Huang F; Hua X; Yang S; Yuan C; Zhang W
Antiviral Res; 2009 Sep; 83(3):274-81. PubMed ID: 19576249
[TBL] [Abstract][Full Text] [Related]
29. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
30. Ritonavir Blocks Hepatitis E Virus Internalization and Clears Hepatitis E Virus In Vitro with Ribavirin.
Primadharsini PP; Nagashima S; Takahashi M; Murata K; Okamoto H
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366538
[TBL] [Abstract][Full Text] [Related]
31. Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication.
Wang W; Wang Y; Debing Y; Zhou X; Yin Y; Xu L; Herrera Carrillo E; Brandsma JH; Poot RA; Berkhout B; Neyts J; Peppelenbosch MP; Pan Q
Antiviral Res; 2017 Apr; 140():1-12. PubMed ID: 28077314
[TBL] [Abstract][Full Text] [Related]
32. Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.
Anang S; Kaushik N; Hingane S; Kumari A; Gupta J; Asthana S; Shalimar ; Nayak B; Ranjith-Kumar CT; Surjit M
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068652
[TBL] [Abstract][Full Text] [Related]
33. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of hepatitis E virus replication by zinc-finger antiviral Protein synergizes with IFN-β.
Yu W; Ji H; Long F; Chen S; He Q; Xia Y; Cong C; Yang C; Wei D; Huang F
J Viral Hepat; 2021 Aug; 28(8):1219-1229. PubMed ID: 33894039
[TBL] [Abstract][Full Text] [Related]
35. Generation of a Bactrian camel hepatitis E virus by a reverse genetics system.
Zhang W; Ami Y; Suzaki Y; Doan YH; Takeda N; Muramatsu M; Li TC
J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34242156
[TBL] [Abstract][Full Text] [Related]
36. Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.
Todt D; Walter S; Brown RJ; Steinmann E
Viruses; 2016 Oct; 8(10):. PubMed ID: 27754363
[TBL] [Abstract][Full Text] [Related]
37. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin.
Lhomme S; DebRoy S; Kamar N; Abravanel F; Metsu D; Marion O; Dimeglio C; Cotler SJ; Izopet J; Dahari H
Viruses; 2019 Jul; 11(7):. PubMed ID: 31323954
[TBL] [Abstract][Full Text] [Related]
38. Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.
Haldipur B; Bhukya PL; Arankalle V; Lole K
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540601
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target.
Qu C; Zhang S; Wang W; Li M; Wang Y; van der Heijde-Mulder M; Shokrollahi E; Hakim MS; Raat NJH; Peppelenbosch MP; Pan Q
FASEB J; 2019 Jan; 33(1):1008-1019. PubMed ID: 30070932
[TBL] [Abstract][Full Text] [Related]
40. Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
Todt D; Friesland M; Moeller N; Praditya D; Kinast V; Brüggemann Y; Knegendorf L; Burkard T; Steinmann J; Burm R; Verhoye L; Wahid A; Meister TL; Engelmann M; Pfankuche VM; Puff C; Vondran FWR; Baumgärtner W; Meuleman P; Behrendt P; Steinmann E
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1731-1741. PubMed ID: 31896581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
